Atacicept is a soluble Fc fusion protein using the naturally occurring TACI receptor to target the two cytokines, BAFF and APRIL, that drive B-cell activity, which are key in the pathogenesis of IgA nephropathy.21 The dual inhibition of BAFF and APRIL by atacicept modulates B-cell activity, reducing the production of Gd-IgA1 and immune complex formation, thus mitigating glomerular inflammation and injury.21 Importantly, this B-cell modulation occurs without evidence of B-cell depletion or immunosuppression, despite stable reductions in Igs, and thus appears amenable to chronic administration. The gene discussed is TNFSF13B; the disease is IgA glomerulonephritis.